Serum Lipoprotein(a) Dynamics before/after Menopause and Long-term Effects of Hormone Replacement Therapy on Lipoprotein(a) Levels in Middle-aged and Older Japanese Women

Abstract

Our results suggest that HRT with CEE plus MPA is useful for the management of elevated serum Lp(a) concentrations in middle-aged and older women. However, follow-up studies are needed to determine whether this finding is related to the future prevention of coronary heart disease events.

Lipoprotein (a): impact by ethnicity and environmental and medical conditions

“…by guest, on www.jlr.org Downloaded from six months of HRT, Lp(a) levels decreased by 19% and remained stable for four years (110). Also, in the Framing ham Offspring Study, the mean plasma Lp(a) concentra tion in postmenopausal subjects was higher than in premenopausal subjects, although no significant differ ence was found after adjustment for age (46).…”

Prevention of Cardiovascular Risk Factors in Postmenopausal Women Receiving Transdermal Hormonal Replacement Therapy

“…The role of estrogens in the regulation of lipid metabolism is multifactorial. They activate the mono-and triglyceride lipoprotein lipases and phospholipases [18]. Moreover estrogens influence the synthesis of receptors binding these enzymes with vascular endothelium [19].…”

“…Generally, Fib concentration in blood serum increases with age but this increase is smaller in women with hormonal replacement therapy in postmenopausal age [5,18,23,24,25].…”

“…According to many studies the influence of hormonal replacement therapies on C and S Proteins and AT III is different [2,5,6,7,12,18,24,26]. Some authors noted the increase of protein C and S [12,20] but others observed decrease of these natural coagulation inhibitors [Fishman et al 2003].…”

Lipoprotein(a) - Structure, Epidemiology, Function and Diagnostics of a Cardiovascular Risk Marker

“…While in premenopausal women with normal menstrual cycles, we observe no or only little alteration of Lp(a) [139][140][141][142], the stimulation with follicle-stimulating hormone (FSH) in the luteal phase will result in a temporary increase [140,142]. Once the women have reached the postmenopausal stage (due to physiological, pharmacological or surgical reasons), the associated hormonal alterations also result in a distinct elevation of Lp(a) [143][144][145][146][147][148]. A hormone replacement therapy with estrogen as a monotherapy or in combination with progesterone leads to a decrease of Lp(a) in these patients, which is particularly marked in those women whose pretherapy Lp(a) concentrations were elevated [143,144,147,148].…”